IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion
ETOP 23-22 RAISE
Phase 2 small_molecule active
Quick answer
IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion for Extensive-disease small cell lung cancer and high SLFN11-expression is a Phase 2 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Partner Therapeutics Limited
- Indication
- Extensive-disease small cell lung cancer and high SLFN11-expression
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active